Sanara MedTech Inc (SMTI)
32.43
+0.08
(+0.25%)
USD |
NASDAQ |
Apr 29, 16:00
Sanara MedTech Research and Development Expense (Quarterly): 0.6515M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.6515M |
| September 30, 2023 | 0.9865M |
| June 30, 2023 | 1.177M |
| March 31, 2023 | 1.317M |
| December 31, 2022 | 1.034M |
| September 30, 2022 | 1.061M |
| June 30, 2022 | 1.067M |
| March 31, 2022 | 0.2046M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.3008M |
| September 30, 2021 | 0.0357M |
| June 30, 2021 | 0.104M |
| March 31, 2021 | 0.1182M |
| December 31, 2020 | 0.0292M |
| September 30, 2020 | 0.011M |
| June 30, 2020 | 0.0415M |
| March 31, 2020 | 0.0044M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.0044M
Minimum
Mar 2020
1.317M
Maximum
Mar 2023
0.509M
Average
0.2527M
Median
Research and Development Expense (Quarterly) Benchmarks
| AptarGroup Inc | -- |
| Daxor Corp | -- |
| Precision Optics Corp Inc | 0.2217M |
| Warby Parker Inc | -- |
| Perspective Therapeutics Inc | 6.08M |